Neurocrine Biosciences had its Relative Strength (RS) Rating upgraded from 68 to 75 Wednesday — a welcome improvement, but still below the 80 or higher score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of at least 80 as they begin their largest runs. See if Neurocrine Biosciences can continue to show renewed price strength and clear that threshold.
Neurocrine Biosciences broke out earlier, but has fallen back below the prior 130.46 entry from a cup with handle. In the scenario where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to form. Also understand that the most recent pattern is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one.
The company showed -42% EPS growth in the latest quarterly report, while sales growth came in at 11%. The next quarterly numbers are expected on or around Aug. 5.
The company holds the No. 21 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Anbio Biotechnology and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
